title: The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: a systematic evaluation.
abstract: This study was aimed to systematically evaluate results of trials examining the effects of omega-3 polyunsaturated fatty acid (n-3 PUFA) consumption on body weight, lean body mass, resting energy expenditure, and overall survival in pancreatic cancer patients. We searched Medline, Pubmed, Embase, and Cochrane databases. We selected randomized controlled trials of n-3 PUFA vs. conventional nutrition in unresectable pancreatic cancer patients. We analyzed our data using the Cochrane statistical package RevMan 5.1. Eleven trials met our inclusion criteria. There was a significant increase in body weight [weighted mean difference (WMD) = 0.62; 95% confidence interval (CI), 0.54-0.69, P < 0.00001) and lean body mass (WMD = 0.96; 95% CI, 0.86-1.06, P < 0.00001), a significant decrease in resting energy expenditure (WMD = -29.74; 95% CI, -55.89-3.59, P = 0.03), and an increase in overall survival (130-259 days vs. 63-130 days) in unresectable pancreatic cancer patients who consumed an oral nutrition supplement enriched with n-3 PUFAs compared to those who consumed conventional nutrition. This preliminary study suggests that n-3 PUFAs are safe and have a positive effect on clinical outcomes and survival in pancreatic cancer patients.
authors.affiliation: a Department of Oncology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
authors.forename: Ying-Jie
authors.initials: YJ
authors.lastname: Ma
authors.forename: Jing
authors.initials: J
authors.lastname: Yu
authors.forename: Jing
authors.initials: J
authors.lastname: Xiao
authors.forename: Bang-Wei
authors.initials: BW
authors.lastname: Cao
mesh_terms: D001481:Basal Metabolism; D002100:Cachexia / Q000209:etiology / Q000517:prevention & control*; D003131:Combined Modality Therapy / Q000009:adverse effects; D015525:Fatty Acids, Omega-3 / Q000009:adverse effects / Q000627:therapeutic use*; D005527:Food, Fortified / Q000009:adverse effects; D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000178:diet therapy* / Q000378:metabolism / Q000628:therapy; D010257:Paraneoplastic Syndromes / Q000209:etiology / Q000517:prevention & control*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic
chemical_list: D015525:Fatty Acids, Omega-3